MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
DarioHealth Corp. DPO Ratio 2011-2025 | DRIO
Annual DPO Ratio DarioHealth Corp.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 43.9 | 75.3 | 83.7 | 179 | 122 | 167 | 175 | 197 | 213 | 114 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 213 | 43.9 | 137 |
Quarterly DPO Ratio DarioHealth Corp.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 157 | 116 | 92 | - | 77.3 | 99.1 | 73.8 | - | 53 | 37.3 | 49.2 | - | 50 | 67.9 | 105 | - | 76.3 | 112 | 136 | - | 152 | 197 | 213 | - | 152 | 114 | 115 | - | 166 | 153 | 168 | - | 154 | 199 | - | - | 254 | 200 | 190 | - | 221 | 218 | 259 | - | 110 | 107 | 140 | - | - | - | 147 | - | 84.1 | 124 | 70.8 | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 259 | 37.3 | 134 |
DPO Ratio of other stocks in the Diagnostics research industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
120 | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
21.3 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
125 | $ 15.82 | 0.44 % | $ 170 M |  China |
 |
Accelerate Diagnostics
AXDX
|
125 | - | -61.36 % | $ 2.46 M |  USA |
 |
Biocept
BIOC
|
56.3 | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
104 | $ 1.55 | -4.63 % | $ 1.97 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
45.8 | - | - | $ 562 M |  Britain |
 |
DexCom
DXCM
|
70.4 | $ 65.83 | -1.69 % | $ 25.4 B | USA |
 |
Castle Biosciences
CSTL
|
52 | $ 39.06 | 1.11 % | $ 1.08 B | USA |
 |
Chembio Diagnostics
CEMI
|
52.5 | - | 0.22 % | $ 16.8 M | USA |
 |
Exact Sciences Corporation
EXAS
|
139 | $ 101.64 | 0.14 % | $ 18.8 B | USA |
 |
Danaher Corporation
DHR
|
66.4 | $ 227.72 | 0.54 % | $ 166 B | USA |
 |
Fulgent Genetics
FLGT
|
34.9 | $ 27.0 | -0.52 % | $ 816 M | USA |
 |
Global Cord Blood Corporation
CO
|
17.7 | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
61.4 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
780 | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
43.5 | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
47.4 | - | -11.32 % | $ 2.94 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
8.98 | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
44.2 | $ 19.98 | -2.82 % | $ 1.07 B | USA |
 |
Enzo Biochem
ENZ
|
52.3 | - | -8.98 % | $ 14.8 K | USA |
 |
Anixa Biosciences
ANIX
|
1.29 K | $ 3.3 | -7.82 % | $ 105 K | USA |
 |
Co-Diagnostics
CODX
|
106 | $ 0.29 | -14.47 % | $ 8.51 M | USA |
 |
IQVIA Holdings
IQV
|
126 | $ 222.75 | 0.24 % | $ 40.4 B | USA |
 |
Guardant Health
GH
|
83.6 | $ 103.7 | 1.6 % | $ 12.7 B | USA |
 |
Aspira Women's Health
AWH
|
112 | - | -6.19 % | $ 10.5 M | USA |
 |
Heska Corporation
HSKA
|
39.7 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
112 | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
56.3 | $ 134.4 | -0.35 % | $ 21.4 B | USA |
 |
Charles River Laboratories International
CRL
|
24.5 | $ 197.62 | 2.4 % | $ 10.2 B | USA |
 |
Quotient Limited
QTNT
|
86.2 | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Mettler-Toledo International
MTD
|
53.4 | $ 1 410.02 | 1.15 % | $ 29.9 B | Schweiz |
 |
Quest Diagnostics Incorporated
DGX
|
18.3 | $ 183.96 | 0.79 % | $ 20.4 B | USA |
 |
NeoGenomics
NEO
|
20.7 | $ 12.03 | 1.48 % | $ 1.52 B | USA |
 |
Neogen Corporation
NEOG
|
62.7 | $ 6.85 | -0.22 % | $ 1.49 B | USA |
 |
Myriad Genetics
MYGN
|
42 | $ 7.04 | -2.36 % | $ 638 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
33.1 | $ 262.89 | -0.48 % | $ 22.1 B | USA |
 |
ICON Public Limited Company
ICLR
|
6.52 | $ 184.38 | -1.18 % | $ 15.2 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
27 | $ 698.77 | -0.77 % | $ 57.6 B | USA |
 |
Lantheus Holdings
LNTH
|
25.3 | $ 66.4 | -0.33 % | $ 4.59 B | USA |
 |
Agilent Technologies
A
|
50.1 | $ 140.3 | 0.46 % | $ 42.7 B | USA |
 |
Biomerica
BMRA
|
32.4 | $ 2.48 | -2.65 % | $ 5.7 M | USA |
 |
Bioventus
BVS
|
59.2 | $ 7.49 | -0.86 % | $ 469 M | USA |
 |
Pacific Biosciences of California
PACB
|
33.5 | $ 2.13 | 0.24 % | $ 540 M | USA |
 |
Motus GI Holdings
MOTS
|
1.72 | - | -34.28 % | $ 263 K |  Israel |